A Phase I, 2-Part, Open-label, Multiple Oral Dose Study of the Safety, Tolerability and Pharmacokinetics of up to 2 Formulations of SMT C1100 in Healthy Adult Male Subjects and a Selected Formulation of SMT C1100 in Paediatric Subjects with Duchenne Muscular Dystrophy (DMD)
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Ezutromid (Primary)
- Indications Duchenne muscular dystrophy
- Focus Pharmacokinetics
- 22 Jun 2017 According to a Summit Therapeutics media release, data from this trial will be presented at the European Paediatric Neurology Society Congress.
- 08 Sep 2016 Positive results (interim data) from this trial are reported, according to Summit Therapeutics media release.
- 09 Aug 2016 Results from second part of the trial in children with DMD published in a Summit Therapeutics media release.